- Amycretin, a new weight loss drug developed by Novo Nordisk, has shown promising early results and is potentially more effective than the company’s established treatments, Ozempic and Wegovy.
- In a phase 1 trial, the drug was found to significantly reduce body weight by 13% over 3 months — a noteworthy improvement compared to the 6% reduction seen with earlier drugs.
- Despite the need for further research to fully understand amycretin’s long-term safety and effectiveness, these findings sparked an increase in Novo Nordisk’s stock prices as well as a heightened interest in GLP-1 agonist medications.
Early findings from a phase 1 clinical trial announced by the Danish company Novo Nordisk, show that amycretin — an experimental drug they have developed to treat obesity — may be significantly more effective than Ozempic and Wegovy (semaglutide) at improving weight loss.
The company has not yet published the data in a peer-reviewed journal, nor has it specified when it might do so.
This may not come as a surprise, seeing that both Ozempic and Wegovy are primarily prescribed for adults with type 2 diabetes to help them control blood sugar levels.
Of the two, only Wegovy has gained Food and Drug Administration (FDA)
Both medications belong to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, and work by mimicking the action of a hormone that helps regulate blood sugar levels and appetite.
Early results suggest that amycretin led to a 13% reduction in body weight over a 3-month period.
Previous
Experts, however, have stressed the need for more comprehensive research to verify the long-term benefits and safety profile of amycretin.
Despite these cautions, Novo Nordisk’s stock value surged by over 8% following the drug’s…
Read the full article here